story of the week
Residual Cancer Burden Score May Predict a Patient’s Residual Risk After Neoadjuvant Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
Lancet Oncol 2021 Dec 10;[EPub Ahead of Print], C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, AS Hamy, M Laé, F Reyal, GS Sonke, TG Steenbruggen, M van Seijen, J Wesseling, M Martín, M Del Monte-Millán, S López-Tarruella, , JC Boughey, MP Goetz, T Hoskin, R Gould, V Valero, SB Edge, JE Abraham, JMS Bartlett, C Caldas, J Dunn, H Earl, L Hayward, L Hiller, E Provenzano, SJ Sammut, JS Thomas, D Cameron, A Graham, P Hall, L Mackintosh, F Fan, AK Godwin, K Schwensen, P Sharma, AM DeMichele, K Cole, L Pusztai, MO Kim, LJ van 't Veer, LJ Esserman, WF SymmansFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.